Fu XM, et al. - In this retrospective analysis, researchers investigated whether trastuzumab is feasible as maintenance or palliative therapy for patients with human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). They analyzed data from 11 patients, among whom, one achieved partial response, six achieved stable disease, and four were assessed as progressive disease. The main focus was on the effectiveness and safety of trastuzumab as well as the prognostic factors for trastuzumab treatment. Left ventricular ejection fraction (LVEF) reduction, fatigue, and anorexia were reported as the most common adverse events. Seven of 11 patients showed LVEF reduction, but the absolute decline in the LVEF was within 10% of baseline. There was an association between tumor marker changes and effectiveness and HER2 status and progression-free survival. HER2 status and overall survival showed no correlation. Overall, for patients with HER2-positive metastatic GC, trastuzumab was found to be feasible as maintenance or palliative therapy.